Thymosin Alpha-1

What Thymosin Alpha-1 is

Thymosin Alpha-1 (Tα1) is a highly conserved, 28-amino-acid acidic peptide derived from a larger precursor protein called prothymosin alpha, produced naturally by thymic epithelial cells ^[1]. It belongs to the thymosin family of peptides—small proteins concentrated in the thymus, the organ responsible for educating T lymphocytes—and is classified as an endogenous immunomodulatory polypeptide among the broader group of thymic hormones ^[2]. Tα1 has a molecular weight of approximately 3,108 daltons and is distinguished by a characteristic N-terminal acetyl group that confers metabolic stability and contributes to its biological activity ^[7].

The discovery of Tα1 traces back to the laboratory of Dr. Allan L. Goldstein, who began systematically fractionating calf thymus tissue extracts in the late 1960s and early 1970s ^[6]. His group isolated a complex protein mixture called thymosin fraction 5 (TF5), which was shown to restore immune function in thymectomized animals and to stimulate lymphocyte differentiation ^[6]. The promising results with TF5 provided the scientific rationale to further purify its active components. Tα1 was first isolated from TF5 in 1977, when Goldstein and colleagues published its isolation and sequence analysis in the Proceedings of the National Academy of Sciences, and it was found to be 10–1,000 times more potent than TF5 in in vivo and in vitro assays of T-cell activity ^[5]. Solid-phase peptide synthesis of an identical molecule was achieved shortly thereafter, eliminating dependence on biological extraction and enabling reproducible clinical research ^[6]. The synthetic form, thymalfasin, has since been approved by regulatory agencies in over 35 countries under the brand name Zadaxin® for clinical use in viral infections and as an immune adjuvant ^[3].

What it is being researched for

1. Viral Infections (Hepatitis B & C, COVID-19)

Tα1's most extensively studied applications involve viral infections. Numerous human trials have evaluated it in chronic hepatitis B, with early studies reporting meaningful rates of HBV DNA clearance compared with historical controls ^[8]. In hepatitis C, trials combining Tα1 with interferon-based regimens have produced mixed results; benefits were seen in some patient populations but definitive superiority over standard-of-care has not been established ^[2]. During the COVID-19 pandemic, Tα1 was deployed widely in China as an immune-regulatory adjunct, and a multicenter cohort study reported that Tα1-treated patients with severe COVID-19 had higher rates of T-cell restoration ^[9]. A separate retrospective study enrolling 1,388 non-severe COVID-19 patients found that Tα1 was associated with shorter viral RNA shedding duration and shorter hospital stays, though it did not significantly prevent progression to severe disease or reduce mortality in that milder cohort ^[10]. Results across COVID-19 studies remain inconsistent, and their observational, non-randomized designs limit causal conclusions ^[9].

2. Cancer Immunotherapy and Oncology Adjuvant Use

Preclinical and clinical evidence suggests that Tα1 may augment anti-tumor immunity through several mechanisms, including reversing macrophage polarization, enhancing natural killer cell activity, and converting immunologically 'cold' tumors—those with poor immune infiltration—toward a 'hot' state more responsive to treatment ^[1]. In surgically resectable non-small cell lung cancer (NSCLC) and liver cancers, studies reported significant improvements in overall survival in the adjuvant setting ^[1]. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 1,704 gastric cancer patients found that Tα1 combined with chemotherapy was associated with higher objective response rates and better quality-of-life scores ^[4]. In locally advanced, unresectable NSCLC, Tα1 was reported to reduce chemoradiation-induced lymphopenia and pneumonia ^[1]. Pilot studies in advanced melanoma have suggested that thymalfasin may improve the efficacy of dacarbazine-based regimens, and more recent investigations have explored synergy with immune checkpoint inhibitors ^[3]. While these findings are encouraging, many oncology studies are small, conducted predominantly in China, and require replication in large, placebo-controlled international trials.

3. Sepsis and Critical Illness

Sepsis involves a dysregulated immune response that frequently progresses to immunosuppression, making immunomodulation a compelling research target ^[5]. Tα1 has been studied as adjunctive therapy in sepsis, with the landmark ETASS trial (a multicenter, single-blind, randomized controlled trial) providing foundational human data ^[8]. A 2025 systematic review and meta-analysis pooling data from 1,972 patients found that Tα1 treatment was associated with a statistically significant reduction in 28-day all-cause mortality compared with placebo, though trial sequential analysis indicated the overall evidence base remains inconclusive and that high-quality multi-center results did not uniformly match pooled findings ^[5]. A subsequent Phase 3 double-blind placebo-controlled trial (TESTS) was published in 2025, offering updated and more rigorous evidence ^[8]. Despite promising signals—particularly in subgroups such as septic patients with cancer or diabetes—the evidence is not yet sufficient for broad therapeutic conclusions, and expert bodies continue to call for well-designed trials.

4. Aging, Immunosenescence, and Vaccine Response

The thymus gland undergoes progressive involution with age, shrinking by approximately 90% by age 65, and with it the endogenous production of Tα1 declines ^[6]. Researchers have proposed that exogenous Tα1 supplementation may partially counteract age-related immune dysfunction, a concept supported by both preclinical and clinical data ^[3]. A 2025 review published in the International Journal of Molecular Sciences documented that Tα1 exhibits immunomodulatory, anti-inflammatory, and antioxidant properties, and that preclinical and clinical studies show it can improve vaccine responses in elderly individuals and mitigate immunosenescence by stimulating T-cell differentiation and enhancing thymic output ^[3]. One area attracting particular attention is vaccine adjuvant use: a randomized controlled trial summarized in the Annals of the New York Academy of Sciences concluded that the findings warranted further examination of Tα1's role in augmenting specific vaccine responses in the elderly and in situations with suboptimal antigen availability ^[7]. An active ClinicalTrials.gov study (NCT06821100) is currently evaluating thymalfasin as an enhancer of COVID-19 vaccine response in older adults ^[11].

5. Autoimmune and Inflammatory Conditions

A distinctive feature of Tα1 is its apparent bidirectional regulatory capacity: it can stimulate suppressed immune responses while simultaneously dampening excessive inflammation. Research in patients with chronic inflammatory autoimmune diseases has found that Tα1 can attenuate the immunogenic and inflammatory activity of myeloid dendritic cells through an indoleamine 2,3-dioxygenase (IDO)-dependent pathway, qualifying it as a unique pleiotropic peptide capable of fine-tuning the quality of immune responses ^[9]. In the context of cancer immunotherapy, preclinical studies suggest Tα1 may reduce colitis caused by immune checkpoint inhibitors—a clinically significant side effect—potentially offering a protective role that could allow safer combination regimens ^[1]. Research in severe acute pancreatitis (SAP), a condition driven by immune and inflammatory dysregulation, is ongoing; a 2025 meta-analysis of five randomized controlled trials in 706 SAP patients was conducted to systematically evaluate Tα1's immunomodulatory efficacy in this setting, though definitive conclusions remain limited by trial heterogeneity ^[6].

6. Immune Deficiency Syndromes and HIV

The earliest clinical research on Tα1 focused on primary immunodeficiency diseases. Thymosin fraction 5 was first shown to be effective in turning on the immune system in children with DiGeorge syndrome and other thymic dysplasias, establishing the foundational rationale for thymic peptide therapy ^[2]. Tα1 itself has subsequently been investigated in DiGeorge syndrome and in HIV/AIDS, conditions characterized by severe deficits in T-cell number and function [2, 8]. Its synthetic form has been studied either as monotherapy or in combination with antiretroviral regimens, with research exploring whether it can increase CD4+ T-lymphocyte counts and restore T-cell-mediated responses ^[2]. The evidence base in these areas is largely composed of smaller pilot trials and observational studies, and these applications are considered investigational outside of approved indications.

7. Tumor Microenvironment and Checkpoint Inhibitor Combinations

A growing body of preclinical evidence explores how Tα1 interacts with the tumor microenvironment (TME). Research published in 2023 and 2026 indicates that Tα1 may promote Th1 polarization, enhance natural killer cell activity, modulate tumor-associated macrophages and myeloid-derived suppressor cells, and contribute to immune surveillance within the TME [1, 3]. Preclinical studies suggest it may augment the efficacy of chemotherapy by reversing efferocytosis-induced M2 macrophage polarization via a TLR7/SHIP1 signaling axis ^[1]. Emerging data also indicates that Tα1 may improve immune infiltration in immunologically cold tumors and may help mitigate certain immune-related adverse events associated with checkpoint inhibitor immunotherapy ^[3]. Clinical investigations in NSCLC, hepatocellular carcinoma, and metastatic melanoma have reported a favorable safety profile, and an active ClinicalTrials.gov study (NCT06178146) is prospectively evaluating Tα1 for immune-related adverse events secondary to immune checkpoint inhibitors ^[4].

How it is thought to work

Tα1 is understood to act as a pleiotropic immunomodulatory signal, meaning it simultaneously influences multiple branches of the immune system rather than a single target. At the molecular level, research has identified Toll-like receptors (TLRs)—particularly TLR2, TLR3, TLR4, TLR7, and TLR9—as key binding partners. Tα1 activates these receptors on dendritic cells and macrophages, triggering downstream signaling cascades including the NF-κB, IRF3, p38MAPK, and MyD88 pathways, which in turn promote the production of pro-inflammatory cytokines such as interferon-alpha (IFN-α), interleukin-12 (IL-12), and interferon-gamma (IFN-γ) [2, 9]. Through TLR-driven dendritic cell maturation, Tα1 enhances antigen presentation—the process by which dendritic cells display pathogen fragments to naive T cells—strengthening the bridge between innate sensing and adaptive immune responses ^[3].

At the cellular level, Tα1 promotes the maturation and differentiation of immature thymocytes into functional CD4+ helper T cells and CD8+ cytotoxic T cells, upregulating the expression of T-cell surface markers including CD3, CD4, and CD8 [2, 6]. It also promotes Th1 polarization—shifting the immune response toward cell-mediated, pathogen-clearing immunity in conditions where a Th2-dominant (antibody-biased) environment has impaired pathogen clearance, as is common in chronic hepatitis B ^[3]. Notably, Tα1 also exhibits regulatory properties: it can attenuate overactive inflammatory responses through an IDO-dependent pathway in myeloid dendritic cells, helping to balance immune activation against immune tolerance ^[9]. This dual capacity to enhance suppressed immunity while moderating excessive inflammation is a defining and scientifically distinctive feature of the peptide [2, 9].

Where the evidence stands

The evidence base for Tα1 spans several decades, multiple disease contexts, and all tiers of study design, but the strength and consistency of findings vary considerably by indication. In viral hepatitis, early randomized controlled trials in hepatitis B showed meaningful HBV DNA clearance rates, and thymalfasin has received regulatory approval in multiple countries based on this body of evidence ^[8]. In COVID-19, a systematic review and meta-analysis published in 2022 evaluated multiple observational cohort studies, and while some reported improved T-cell counts, shorter viral shedding, and reduced mortality in severe cases, the overall results remained heterogeneous and inconclusive due to non-randomized, retrospective designs and confounding by indication—Tα1 was more often given to sicker patients, complicating outcome comparisons [9, 10]. In sepsis, a Phase 3 double-blind randomized controlled trial (TESTS, 2025) and a companion meta-analysis of 1,972 patients represent the most rigorous human data, with pooled analyses suggesting a reduction in 28-day mortality, though trial sequential analysis has flagged ongoing uncertainty [5, 8]. In oncology, most human data comes from smaller randomized trials and cohort studies concentrated in Asian research centers, with a recent meta-analysis of 20 RCTs in gastric cancer showing improved objective response rates when Tα1 was combined with chemotherapy ^[4].

The key gaps and limitations in the current evidence include: a heavy reliance on studies conducted in China, which may limit generalizability; a predominance of small or open-label trials in early-phase oncology research; significant heterogeneity in patient populations, disease severity, and co-interventions across studies; and an absence of long-term follow-up data for most applications. The aging and immunosenescence literature relies substantially on preclinical models and small clinical studies, with large-scale randomized trials in this population still ongoing [3, 11]. Preclinical (cell and animal) studies have been instrumental in elucidating TLR-based mechanisms, tumor microenvironment interactions, and macrophage polarization effects, but translation to human outcomes has not been uniformly demonstrated. Overall, Tα1 has a well-established safety and tolerability profile across thousands of treated patients, but the evidence for efficacy in most applications beyond approved hepatitis B indications remains promising yet incomplete [1, 2].

Frequently asked questions

What is Thymosin Alpha-1 and where does it come from?

Thymosin Alpha-1 is a 28-amino-acid peptide produced naturally by thymic epithelial cells in the human thymus gland. It was first isolated from calf thymus tissue by Dr. Allan L. Goldstein and colleagues in 1977 and belongs to a broader family of proteins called thymosins. Its synthetic form, thymalfasin, is chemically identical to the naturally occurring molecule and is used in research and approved clinical settings globally.

What is Thymosin Alpha-1 studied for?

Tα1 is primarily studied for its immunomodulatory effects. Research has investigated it across viral infections including hepatitis B, hepatitis C, and COVID-19; as a cancer immunotherapy adjuvant in conditions such as non-small cell lung cancer, hepatocellular carcinoma, and melanoma; in sepsis and critical illness; in age-related immune decline; and as a vaccine adjuvant in immunocompromised or elderly populations.

Is Thymosin Alpha-1 (Zadaxin) approved anywhere?

Yes. The synthetic form of Tα1, sold under the brand name Zadaxin® (thymalfasin), has received regulatory approval in over 35 countries—predominantly in Asia and parts of Europe—for the treatment of chronic hepatitis B and as an immune adjuvant for vaccines in immunocompromised individuals. It has not received approval from the U.S. FDA and is not on the FDA's approved compounding bulk substances list.

How does Thymosin Alpha-1 affect the immune system?

Tα1 acts on multiple components of both innate and adaptive immunity. It activates Toll-like receptors (TLRs) on dendritic cells and macrophages, triggering cytokine production and promoting dendritic cell maturation. It also stimulates the differentiation of immature immune cell precursors into functional CD4+ helper and CD8+ cytotoxic T cells, and promotes a shift toward Th1-type cell-mediated immunity. Uniquely, it can also moderate excessive inflammatory responses, suggesting a regulatory as well as stimulatory role.

Has Thymosin Alpha-1 been tested in human clinical trials?

Yes, Tα1 has a substantial clinical trial history spanning several decades and thousands of patients. Notable studies include randomized controlled trials in hepatitis B and C, a Phase 3 double-blind placebo-controlled trial in sepsis (TESTS, 2025), multiple randomized trials in cancer patients, and cohort studies in COVID-19. An active ClinicalTrials.gov study (NCT06821100) is currently enrolling older adults to evaluate Tα1 as a vaccine response enhancer.

What does research show about Thymosin Alpha-1 and aging?

As the thymus involutes with age, endogenous Tα1 production declines, which has been linked to reduced T-cell function and poor vaccine responsiveness in elderly individuals. A 2025 review in the International Journal of Molecular Sciences found that Tα1 can improve vaccine responses in elderly subjects and mitigate immunosenescence by stimulating T-cell differentiation and enhancing thymic output. Researchers consider this a promising area, though large-scale long-term trials in aged populations are still needed.

What is the difference between Thymosin Alpha-1 and Thymosin Beta-4?

Despite both belonging to the thymosin family of peptides, these are structurally and functionally distinct molecules. Thymosin Alpha-1 is a 28-amino-acid peptide focused primarily on immune regulation and T-cell maturation. Thymosin Beta-4 is a 43-amino-acid actin-sequestering protein involved in cell migration and tissue repair, and is studied in the context of wound healing and cardiac repair. They do not share the same mechanism of action or primary research indications.

What are the known safety findings for Thymosin Alpha-1 in research?

Across clinical trials and observational studies covering thousands of patients—including those with hepatocellular carcinoma, non-small cell lung cancer, melanoma, and hepatitis B and C—Tα1 has consistently demonstrated a favorable tolerability profile with no serious treatment-related adverse events reported at rates above placebo in the major trials. Research reporting also notes it does not interact with the hypothalamic-pituitary-gonadal axis. As with any investigational compound, ongoing research continues to characterize its safety profile in new populations and combinations.

Is Thymosin Alpha-1 the same as prothymosin alpha?

No, though they are related. Prothymosin alpha is a larger precursor protein, and Thymosin Alpha-1 is a shorter 28-amino-acid peptide fragment derived from it by proteolytic cleavage. Tα1 is the biologically active immunomodulatory form that has been characterized in research and approved for clinical use, while prothymosin alpha itself has distinct biological properties.

Can Thymosin Alpha-1 be used with immune checkpoint inhibitors in cancer research?

This is an active area of preclinical and early clinical investigation. Preclinical studies suggest Tα1 may enhance anti-tumor immunity by converting immunologically 'cold' tumors to 'hot' ones and may also mitigate certain immune-related adverse events caused by checkpoint inhibitors, such as colitis. Human data from a ClinicalTrials.gov study (NCT06178146) is being collected prospectively. These combination approaches remain investigational and are not yet supported by definitive Phase 3 trial evidence.

Glossary

Thymalfasin

The International Nonproprietary Name (INN) for synthetic Thymosin Alpha-1, sold commercially as Zadaxin® and approved in over 35 countries for hepatitis B treatment and vaccine adjuvant use.

Thymosin Fraction 5 (TF5)

A partially purified, heat-stable extract of calf thymus tissue containing a complex mixture of peptides that was shown to restore T-cell immune function in thymectomized animals; the source material from which Tα1 was first isolated.

Immunosenescence

The gradual deterioration of immune system function that occurs with aging, characterized by reduced T-cell output from the thymus, impaired vaccine responses, and increased susceptibility to infection and cancer.

Toll-like Receptors (TLRs)

Pattern recognition receptors of the innate immune system located on dendritic cells, macrophages, and other immune cells that detect molecular signatures from pathogens and activate downstream immune signaling cascades; several TLRs (TLR2, TLR3, TLR4, TLR7, TLR9) are implicated as Tα1 binding partners.

Th1/Th2 Polarization

The differentiation of CD4+ helper T cells into either Th1 cells, which drive cell-mediated immunity against intracellular pathogens and tumors, or Th2 cells, which favor antibody-mediated responses; Tα1 is studied for its ability to shift this balance toward Th1 responses in contexts where Th2 dominance impairs clearance of chronic infections.

Thymic Involution

The age-related shrinkage of the thymus gland, which reduces its output of mature T cells and thymic peptides like Tα1, and is considered a major driver of immune aging.

Pleiotropic

Having multiple, diverse biological effects; in the context of Tα1, this refers to its ability to simultaneously influence T cells, dendritic cells, macrophages, natural killer cells, and cytokine networks across both innate and adaptive immunity.

Tumor Microenvironment (TME)

The complex cellular and molecular milieu surrounding a tumor, including immune cells, blood vessels, and signaling molecules, which can either suppress or facilitate anti-tumor immune responses; Tα1 is studied for its ability to modulate the TME toward an immune-permissive state.

References

1. Thymosin alpha 1 – Reimagine its broader applications in the immuno-oncology era — International Immunopharmacology, 2023 (doi: 10.1016/j.intimp.2023.109952)
2. Immune Modulation with Thymosin Alpha 1 Treatment — Vitamins and Hormones, 2016 (doi: 10.1016/bs.vh.2016.04.003)
3. Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives — European Journal of Pharmacology, 2026 (doi: 10.1016/j.ejphar.2026.179277)
4. Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials — Frontiers in Immunology, 2026
5. Thymosin-α1 for Sepsis Management: A Systematic Review and Meta-Analysis of 1972 Patients — PubMed Central / PMC, 2025
6. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis — PubMed Central / PMC, 2025
7. Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries — Annals of the New York Academy of Sciences, 2007 (doi: 10.1196/annals.1415.050)
8. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial — PubMed / PMC12123687, 2025
9. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes — International Immunopharmacology, 2022 (doi: 10.1016/j.intimp.2022.109584)
10. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study — Frontiers in Immunology, 2021 (doi: 10.3389/fimmu.2021.673693)
11. Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine (NCT06821100) — ClinicalTrials.gov, The Methodist Hospital Research Institute, 2025–ongoing